课题基金 / 基金详情

SUPRAVENTRICULAR TACHYCARDIA AND SYNCOPE IN HYPERTROPIC CARDIOMYOPATHY

SUPRAVENTRICULAR TACHYCARDIA AND SYNCOPE IN HYPERTROPIC CARDIOMYOPATHY
肥厚型心肌病中的室上性心动过速和晕厥
批准号:
3966725
负责人:
R O CANNON
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

R O CANNON的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Syncope is a frequent symptom in patients with hypertrophic cardiomyopathy, and may be caused by ventricular tachycardia in many patients, due to a fall in cardiac output. Supraventricular tachycardia is generally well tolerated by patients with normal left ventricles, and rarely results in syncope. To examine the effect of supraventricular tachycardia in hypertrophic cardiomyopathy, rapid atrial pacing at a heart rate of 150 was performed with measurement of mean blood pressure in 25 patients with hypertrophic cardiomyopathy and 21 patients with normal left ventricles. Coronary flow was estimated in the great cardiac vein in 12 patients with hypertrophic cardiomyopathy and 8 patients with normal left ventricles, all with normal epicardial coronary arteries. In comparison to patients with normal left ventricles, patients with hypertrophic cardiomyopathy demonstrated a marked fall in systemic blood pressure during rapid atrial pacing. This may relate to a fall in preload due to shortened diastolic filling period and loss of coordinated atrial systole in a noncompliant ventricle operating on an ascending limb of the Starling curve, resulting in a fall in stroke work. The fall in blood pressure also resulted in a marked fall in coronary flow, which may cause myocardial ischemia and left ventricular dysfunction. Thus, supraventricular tachycardia, simulated by rapid atrial pacing, may account for presyncope and syncope in many patients with hypertrophic cardiomyopathy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EFFECT OF SURGICAL RELIEF OF OBSTRUCTION IN HYPERTROPHIC CARDIOMYOPATHY
HORMONE THERAPY AND INFLAMMATORY CELL ADHESION MOLECULES
ABNORMAL ESOPHAGEAL MOTILITY IN PATIENTS WITH LIMITED CORONARY FLOW RESERVE
DETRIMENTAL EFFECT OF ERGONOVINE IN HYPERTROPHIC CARDIOMYOPATHY